However, there still remain challenges to precisely control the administrations of drugs and Dsi RNPs in vivo before the clinical applications, because Dsi RNPs are required to be administered earlier than anticancer chemotherapeutics for the best synergistic cancer suppression. The gene discussed is P4HB; the disease is cancer.